AIM ImmunoTech Inc. Common Stock AIM 深 沪
等待开盘 05-20 09:30:00 美东时间
0.411
+0.003
+0.74%
华盛通- 最 高0.4282
- 今 开0.3666
- 成交量 1305.73万股
- 最 低 0.33
- 昨 收 0.408
- 总市值 641.15万
- 52周最高 20.3297
- 市盈率 静 --
- 换手率 83.70%
- 52周最低 0.241
- 委 比 0.00%
- 总股本 1559.97万
- 历史最高 20.3297
- 量 比 0.14
- 振 幅 24.07%
- 历史最低 0.241
- 每 手 1
- 风险率 2.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market trading include AMST, HAO, MTVA, ONCO, SDA, PIII, VRAX, PURR, BKKT, WOK, BTM, and UBXG.
05-19 16:47
AIM ImmunoTech shares are trading higher. The company reported Q1 financial results.
AIM ImmunoTech shares are trading higher. The company reported Q1 financial res...
05-18 20:41
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
AIM ImmunoTech Q1 EPS $(0.69) Down From $(0.05) YoY, Sales $22.000K Miss $100.000K Estimate
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.69) per share. This is a 1280 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $22.000
05-16 06:41
Transcript: Aimia Q1 2026 Earnings Conference Call
On Wednesday, Aimia (TSX:AIM) discussed first-quarter financial results during ...
05-13 21:47
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
AIM ImmunoTech Raises Capital Through Warrant Exercise Inducement
AIM ImmunoTech ( ($AIM) ) just unveiled an update. On May 8, 2026, AIM ImmunoTe...
05-13 05:29
AIM ImmunoTech Announces Final Primary Endpoint Report On Objective Response Rate Data From Phase 2 Trial Evaluating Ampligen, With Topline Results Indicating 50% Objective Response Rate, Including 21% Complete Responses
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center ("UPMC") Phase 2 clinical trial –
05-07 20:26
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Agilon Health (NYSE:AGL) stock increased by 22.1% to $34.0 during Wedn...
05-07 05:03
AIM ImmunoTech Provides Routine Update on Annual Filings
AIM ImmunoTech Inc. (NYSE American: AIM) announced that its audited financial statements for the fiscal year ended December 31, 2025, included an audit report with a going concern emphasis of matter. The company remains confident in its ability to secure funding due to promising results from its lead drug, Ampligen, in treating late-stage pancreatic cancer. AIM recently reported positive progress in the Phase 2 DURIPANC study combining Ampligen w...
04-13 22:00
